Search Results For ''

  • Rex teams up with Etihad Airways to expand global connectivity

    In a bid to enhance travel options for passengers, Rex Airlines (ASX: REX) has confirmed a major partnership with Etihad Airways, one of the world’s leading airlines based in the United Arab Emirates. This collaboration between Rex and Etihad is set to give passengers in both Australia and abroad more flexibility with their travel in

    Read More
    Public
  • Defense Support and Auxiliary Equipment Market to Grow at 6.74% CAGR By 2029

    Technological advancements, geopolitical tensions, and military modernisation programs are the factors driving market in the forecast period 2025-2029. According to TechSci Research report, “Defense Support and Auxiliary Equipment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, The Global Defense Support and Auxiliary Equipment Market stood at USD 153.85 Billion in 2023 and

    Read More
    Public
  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment

    Biotech company Mesoblast (ASX: MSB) has received positive feedback from the US Food and Drug Administration (FDA) for a new heart failure treatment called rexlemestrocel-L. This treatment aims to help people with severe heart failure, particularly those who have reached the end stages of the condition. Heart failure affects millions of people worldwide, with many

    Read More
    Public
  • Archer Materials reduces size of biochip gFET chip by 97%

    Semiconductor company Archer Materials (ASX: AXE) has achieved a major milestone in its Biochip technology development by significantly reducing the size of its gFET (graphene field-effect transistor) chip. This achievement resulted from redesigning the circuit layouts, leading to a substantial decrease in chip size that has the potential to increase its utility in medical diagnostics.

    Read More
    Public
  • Magic mushrooms company Tryp prepares for ASX listing via $14.3m backdoor merger with Exopharm

    Canadian biotech company Tryp Therapeutics (CSE: TRYP) is set to list on the ASX through a backdoor merger with genetic medicines developer Exopharm (ASX: EX1) in a $14.3 million acquisition agreement. Following this agreement, Exopharm will change its name to Tryp and re-list on the ASX. On completion of the Transaction (Completion), Exopharm will be

    Read More
    Public
  • US shares reverse from all-time highs, XJO to open lower

    The XJO is expected to open lower this morning following a pullback in the U.S on Friday. Their futures have edged into the red this morning. We managed to break higher on Friday and make fresh highs once again, however, as usual, our new heights are being met with selling. The market remains indecisive and

    Read More
    Public